Videos

In ‘Expanding Clinical Use of PSMA PET in Advanced Prostate Cancer,’ our experts delve into how PSMA PET imaging is being incorporated into treatment decisions for patients with advanced and metastatic prostate cancer.

Daniel Shapiro, MD, FACS, discusses how emerging biomarker strategies and evolving combination therapies are reshaping risk stratification and treatment decision-making in kidney cancer.

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce how clinicians balance the benefits of treatment intensification with the potential for added toxicity in patients with metastatic castration sensitive prostate cancer (mCSPC), particularly in older individuals or those with significant comorbidities.

In this segment, Dr. Charles J. Ryan asks Dr. Murilo De Almeida Luz to discuss how treatment intensification strategies may differ across various clinical presentations of metastatic castration sensitive prostate cancer (mCSPC).

Anjali Kapur, MD, discusses a post-market analysis of the safety of the eCoin implantable tibial nerve stimulator for patients with urge urinary incontinence.

In this video, Gordon A. Brown, DO, FACS, explores post hoc analyses from CAPItello-281 evaluating increasing PTEN deficiency thresholds and their relationship to treatment response.

Dalia Kaakour, MD, MPH, highlights key findings from a retrospective review of cardiovascular system toxicities in patients initiating novel hormonal therapies for advanced prostate cancer.

Bogdana Schmidt, MD, MPH, identified several subgroups most likely to harbor occult systemic disease and therefore potentially benefit from adding immunotherapy to BCG:

Matthew D. Galsky, MD, discusses the mechanism of action for FX-909, a first-in-class agent targeting PPARγ in advanced urothelial carcinoma.

The PRIMARY2 phase 3 trial found that PSMA PET-CT in men with normal or equivocal MRI results safely halved the number of prostate biopsies, maintained non-inferior detection of clinically significant cancer, and reduced insignificant cancer diagnosis by more than half.

Data from the CLIMATE trial indicate that detectable miR-371 post-orchiectomy is a marker of MRD in patients with clinical stage 1 testicular germ cell tumor.

The Hugo RAS system requires wider, offset port placement compared to conventional platforms, and its open console design promotes a more ergonomically sound upright posture that may reduce the cervical spine strain associated with prolonged use of immersive closed-console robotic systems.

Christopher M. Pieczonka, MD, discusses the design and interim findings from the phase 2 QUILT 2.005 trial.

Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies.

Sara Coca Membribes, MD, highlights several emerging therapeutic strategies with near-term clinical implications.

In this segment, Dr. Charles J. Ryan asks Dr. Alan H. Bryce to explain why androgen deprivation therapy (ADT) alone is no longer considered adequate treatment for most patients with metastatic castration sensitive prostate cancer (mCSPC).

In this segment, Dr. Charles J. Ryan asks Dr. Jayram how the concept of survivorship has become an increasingly important consideration in the management of metastatic castration sensitive prostate cancer (mCSPC).

Mark Farha, MD, BSc, MBA, discusses the development of a novel genomic score designed to predict early BCG failure in patients with non–muscle invasive bladder cancer.

Gordon A. Brown, DO, FACOS, reviews rPFS outcomes demonstrating clinical benefit with capivasertib plus abiraterone in PTEN-deficient mHSPC.

According to Chew, Break Wave lithotripsy is best suited to renal and ureterovesical junction stones, where ultrasound visualization is most reliable.

Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.

At 1 year, patients randomized to Rezūm showed a 4.6-point greater improvement on the IPSS symptom score compared with those escalated to combination therapy.

On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review.

Antoni Vilaseca Cabo, MD, characterizes these results as proof of concept for the local delivery approach, with phase 2 and 3 trials now underway.

Guerrero-Ramos argues that landmark survival data from recent trials justify perioperative immunotherapy in muscle-invasive bladder cancer, while acknowledging that validated tools for individual patient selection remain elusive and that urologists must engage closely with medical oncology to deliver optimal care.

On diagnostic pitfalls, Necchi highlights penile cancer as a particularly common source of delay.

On counseling patients who want to avoid cystectomy, Bogdana Schmidt, MD, MPH, points to trimodality therapy as the established bladder-preserving option, supported by longer-term data and propensity-matched analyses showing outcomes comparable to cystectomy in selected patients.

How teams use PSMA PET to stage prostate cancer: who orders, who reads, and how tumor boards refine treatment when findings conflict.

Daniel J. George, MD, discusses results from a survey examining the experiences and unmet needs of caregivers supporting patients with metastatic prostate cancer.

Learn how PSMA PET reshapes prostate cancer staging, outperforms CT and bone scans, and finds recurrence even at very low PSA.